Director Dealings
16 April 2020
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Directors' dealings undertaken for tax planning purposes:
Richard Ross, Chief Scientific Officer sold 125,000 Ordinary Shares at a price of 30 pence per Ordinary Share; his and his wife's (Sarah Ross) respective ISAs purchased 125,000 Ordinary Shares in aggregate at a price of 30.02 pence per Ordinary Share. Following the transactions, the total beneficial interest of Richard Ross and his connected parties remains unchanged at 2,182,420 Ordinary Shares, representing 1.8% of the total voting rights as at 16 April 2020.
Details of the full notifications received by the Company are set out below:
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Richard Ross | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Scientific Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Sale and purchase of ordinary shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
Sale 30p Purchase 30.02p | 125,000 62,500 |
| |||
d)
| Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price | |||||
e)
| Date of the transaction
| 16 April 2020 | |||
f)
| Place of the transaction
| XLON |
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Sarah Ross | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Closely associated person to an Executive Director | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Sale and purchase of ordinary shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
Purchase 30.02p | 62,500 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price | |||||
e)
| Date of the transaction
| 16 April 2020 | |||
f)
| Place of the transaction
| XLON |
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer | |
Richard Bungay, Chief Financial Officer | |
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl | |
Corporate Broking: James Stearns | |
Cantor Fitzgerald Europe (Joint Broker) | +44 (0)20 7894 7000 |
Corporate Finance: Phil Davies, Will Goode, Luke Philippou | |
Healthcare Equity Sales: Andrew Keith | |
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell |
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-headquartered, European-based specialty pharma company developing pharmaceutical products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.